Research advances in neuroimaging and genetic characteristics of the non-fluent/agrammatic variant of primary progressive aphasia
Imagine struggling to form a sentence—your thoughts are clear, but the words come out slow, broken, or strained. For people with the non-fluent/agrammatic variant of primary progressive aphasia (naPPA), this is a daily reality. NaPPA is a rare neurodegenerative disorder that erodes language skills while leaving other cognitive abilities intact—at least at first. Now, new research is shedding light on how naPPA affects the brain and its genetic roots, bringing us closer to better diagnosis and treatment.
This review, led by Yi-Jing Bai, Xiao-Wei Liu, and Wei-Dong Le from Dalian Medical University and the Sichuan Academy of Medical Science-Sichuan Provincial Hospital in China, summarizes key advances in neuroimaging and genetics related to naPPA.
What is naPPA?
NaPPA is one of three subtypes of primary progressive aphasia (PPA), a group of diseases where language skills decline gradually. Unlike the semantic variant (which impairs word meaning) or the logopenic variant (which causes pauses while searching for words), naPPA’s hallmark is effortful, non-fluent speech. Patients may mix up sentence structure (agrammatism—e.g., saying “dog walk” instead of “the dog walks”) or struggle to coordinate the muscles needed to talk (apraxia of speech), leading to slurred or fragmented speech.
How naPPA damages the brain
To understand naPPA, researchers use neuroimaging tools to map brain atrophy (shrinkage) and dysfunction:
- Structural MRI: The most common method, it reveals that naPPA primarily affects the left frontal lobe—specifically areas around the Sylvian fissure (a deep groove linked to language). Key regions include the inferior frontal gyrus (critical for grammar) and the insula (involved in speech production). For most people, language is controlled by the left hemisphere, so this left-sided atrophy makes sense. A small number of cases with right-sided language dominance show right hemisphere atrophy instead.
- Progression of atrophy: As naPPA worsens, shrinkage spreads from the frontal lobe to nearby areas: the left temporal lobe (word meaning), the cingulate cortex (attention), and the parietal lobe (spatial awareness).
- Functional imaging: Early on, atrophy may be subtle, so tools like FDG-PET (which measures brain metabolism) help. FDG-PET can detect reduced activity (“hypometabolism”) in language networks before symptoms become severe. For example, low activity in the parietal lobe or brainstem predicts conversion to related disorders like corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP).
Brain changes linked to symptoms
NaPPA disrupts the brain’s language network—a system of regions connected by white matter “highways”:
- Speech fluency: Reduced fluency ties to degeneration in the frontal, parietal, and superior temporal lobes.
- Grammar and syntax: Trouble understanding complex sentences (e.g., “The cat that the dog chased ran away”) links to atrophy in the left inferior frontal cortex (Broca’s area) and anterior temporal lobe.
- Word comprehension: Difficulty understanding words correlates with damage to the temporal lobe’s “reading” areas (fusiform gyrus) and white matter connections linking language regions.
The genetic and pathological roots of naPPA
NaPPA is not a single disease—it’s a clinical syndrome linked to different underlying brain pathologies:
- FTLD-tau (50–70%): Frontotemporal lobar degeneration (FTLD) caused by abnormal tau protein buildup. Tau normally stabilizes brain cells, but mutations in the MAPT gene (chromosome 17) make it form toxic clumps. This is seen in diseases like CBD, PSP, or Pick’s disease.
- FTLD-TDP (20%): FTLD caused by TDP-43 protein buildup (a protein that regulates gene activity). Mutations in the GRN gene (which makes progranulin, a waste-clearing protein) are common here.
- Alzheimer’s disease (12–25%): A smaller number of cases involve amyloid plaques and tau tangles—hallmarks of AD—damaging language regions.
Biomarkers: Clues to diagnosis and progression
Biomarkers—molecules in body fluids that signal disease—are a game-changer for naPPA:
- Neurofilament light chain (NfL): A protein released when brain cells die. Higher levels in cerebrospinal fluid (CSF) or blood correlate with worse symptoms, faster atrophy, and TDP-43 pathology. Blood NfL also helps distinguish naPPA from the logopenic variant.
- Tau ratios: In non-AD naPPA, the ratio of phosphorylated tau (damaged tau) to total tau in CSF hints at whether the cause is tau or TDP-43.
- AD biomarkers: For AD-related naPPA, CSF levels of amyloid-beta42 (plaques) and tau reliably confirm the diagnosis.
What’s next for naPPA?
Currently, no treatments exist to improve or stabilize naPPA’s language deficits. But advances in genetics and imaging are paving the way for precision medicine—treatments tailored to a patient’s specific pathology (e.g., drugs that clear toxic tau or TDP-43).
Because naPPA is rare, researchers stress the need for global collaborations to share data. Large-scale techniques like genomics (studying all genes) and proteomics (studying all proteins) could uncover new biomarkers, making early diagnosis and targeted treatment possible.
Conclusion
NaPPA is a complex disorder, but new research is decoding its brain patterns and genetic triggers. From MRI scans that map early atrophy to blood tests that signal cell damage, we’re getting better at identifying naPPA sooner. And as we learn more about the genes and proteins involved, we move closer to treatments that could slow or stop the disease. For the people living with naPPA, these advances aren’t just science—they’re hope for a future where speaking clearly doesn’t feel like a struggle.
This review was published in the Chinese Medical Journal in 2021 by Yi-Jing Bai, Xiao-Wei Liu, and Wei-Dong Le. The original study is available at doi.org/10.1097/CM9.0000000000001424
Was this helpful?
0 / 0